---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-097781"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-09-06T23:59:59+00:00"
generated_at: "2026-05-31T06:06:29.365720+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics (GANX) enters $50M at-the-market equity offering with Oppenheimer

## Summary
- Equity Distribution Agreement allows sale of up to $50M in common stock via Oppenheimer as agent.
- Oppenheimer will receive a 3.0% commission on gross proceeds; company also reimburses certain expenses.
- Sales will be made under existing shelf registration statement (Form S-3, effective June 1, 2022).
- Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
- Shares offered through Nasdaq or other trading market; no escrow or trust arrangement for proceeds.

## SEC filing metadata
- accession: 0001104659-24-097781
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924097781/0001104659-24-097781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924097781/tm2423330d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-097781
- JSON: https://secwatch.observer/filing/0001104659-24-097781.json
- Plain text: https://secwatch.observer/filing/0001104659-24-097781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.